Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleNuclear Oncology

Radiotherapy, Toxicity and Dosimetry of Copper-64-TETA-Octreotide in Tumor-Bearing Rats

Carolyn J. Anderson, Lynne A. Jones, Laura A. Bass, Elizabeth L.C. Sherman, Deborah W. McCarthy, P. Duffy Cutler, Margaret V. Lanahan, Michael E. Cristel, Jason S. Lewis and Sally W. Schwarz
Journal of Nuclear Medicine November 1998, 39 (11) 1944-1951;
Carolyn J. Anderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynne A. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura A. Bass
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth L.C. Sherman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah W. McCarthy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Duffy Cutler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret V. Lanahan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael E. Cristel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason S. Lewis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally W. Schwarz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 39, Issue 11
November 1, 1998
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiotherapy, Toxicity and Dosimetry of Copper-64-TETA-Octreotide in Tumor-Bearing Rats
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiotherapy, Toxicity and Dosimetry of Copper-64-TETA-Octreotide in Tumor-Bearing Rats
Carolyn J. Anderson, Lynne A. Jones, Laura A. Bass, Elizabeth L.C. Sherman, Deborah W. McCarthy, P. Duffy Cutler, Margaret V. Lanahan, Michael E. Cristel, Jason S. Lewis, Sally W. Schwarz
Journal of Nuclear Medicine Nov 1998, 39 (11) 1944-1951;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiotherapy, Toxicity and Dosimetry of Copper-64-TETA-Octreotide in Tumor-Bearing Rats
Carolyn J. Anderson, Lynne A. Jones, Laura A. Bass, Elizabeth L.C. Sherman, Deborah W. McCarthy, P. Duffy Cutler, Margaret V. Lanahan, Michael E. Cristel, Jason S. Lewis, Sally W. Schwarz
Journal of Nuclear Medicine Nov 1998, 39 (11) 1944-1951;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
  • Monte Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of 64Cu: Comparison with MIRDcell S Values and Implications for Studies of Its Cytotoxic Effects
  • {alpha}V{beta}3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4
  • The Role of p53 in Combination Radioimmunotherapy with 64Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer
  • Preparation and Biological Evaluation of 64Cu-CB-TE2A-sst2-ANT, a Somatostatin Antagonist for PET Imaging of Somatostatin Receptor-Positive Tumors
  • Nuclear Uptake and Dosimetry of 64Cu-Labeled Chelator Somatostatin Conjugates in an SSTr2-Transfected Human Tumor Cell Line
  • Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
  • Melanoma Therapy via Peptide-Targeted {alpha}-Radiation
  • Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
  • Preparation and Biological Evaluation of Copper-64-Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator
  • Subcellular Localization of Radiolabeled Somatostatin Analogues: Implications for Targeted Radiotherapy of Cancer
  • The Inhibitory Effect of 111In-DTPA0-Octreotide on Intrahepatic Tumor Growth After Partial Hepatectomy
  • Copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for the Prevention of Tumor Growth at Wound Sites following Laparoscopic Surgery: Monitoring Therapy Response with microPET and Magnetic Resonance Imaging
  • Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size
  • 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors
  • Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy
  • Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model
  • In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector
  • Google Scholar

More in this TOC Section

  • Dose Escalation Trial of Indium-111-Labeled Anti-Carcinoembryonic Antigen Chimeric Monoclonal Antibody (Chimeric T84.66) in Presurgical Colorectal Cancer Patients
  • Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates
  • Quantifying the Radiation Dosage to Individual Skeletal Lesions Treated with Samarium-153-EDTMP
Show more Nuclear Oncology

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire